Biopix-T Pitch & Q&A | Medtech, Pre-Series A, Greece
BIOPIX-T, headquartered in Heraklion, Crete, was founded in 2019 with the goal of revolutionizing molecular diagnostics at the Point-Of-Care and Home-Testing environments. Their flagship product, Pebble, is a mobile Sars-CoV2 and Flu A detection device that can detect the virus in a sample in less than half an hour.
Why we love Biopix-T
Fully licensed and certified as a medical device designer and manufacturer (ISO13485).
Pan-European free sales certificate (CE IVD) within two years of launch for their products.
Promising commercial traction: 200+ devices sold, 120 active, and over 40,000 tests performed since October 2021.
Backers include Greek VC Metavallon, Bulgarian VC Eleven, and angel investors.
Covid's strong market tailwinds in point-of-care diagnostics (10% CAGR to reach 70B+ in 2027).
Award winner: EU Innovation Radar Key Innovator, John and Mary Pappa John Business Plan Competition, TechTourTop Presenting Company, and more.
Founded by a team from the Foundation for Research and Technology - Hellas' Institute of Molecular Biology and Biotechnology (IMBB-FORTH).
We invite you to discuss Biopix-T's upcoming deal. They'll be giving a presentation on their business, followed by a Q&A.
Join us starting at 5:00 EET on Tuesday, February 14.